SRD5A3 and benign prostatic hyperplasia: In contrast, an overall increasing trend in SRD5A3 expression was observed between the BPH and ADT-PCa subgroups, with the ADT ≤12 months subgroup having the highest relative SRD5A3 expression (median difference of 9.39 in ADT ≤12 months vs the primary PCa group, p = 0.13; median difference of 11.3 in the ADT ≤12 months group vs the BPH group, p = 0.02) (Fig. 1).